107263-89-8

Usage

Uses

Used in Pharmaceutical Industry:
Thiazole, 4-ethynyl-2-methyl-, is used as a key intermediate in the synthesis of various pharmaceutical compounds for its biological and pharmaceutical properties. It aids in the development of drugs that can treat a range of diseases by interacting with specific biological targets.
Used in Agrochemical Industry:
In the agrochemical industry, Thiazole, 4-ethynyl-2-methyl-, is utilized as a building block for the creation of agrochemicals. These agrochemicals can be used for pest control, weed management, and other agricultural applications, contributing to enhanced crop protection and yield.

Upstream product

• 107263-88-7 4-(2-Methyl-4-thiazolyl)1,2,3-selenadiazoles 
• 90965-06-3 dimethyl 1-(1-diazo-2-oxopropyl)phosphonate 
• 20949-84-2 2-methylthiazole-4-carbaldehyde 
• 6436-59-5 ethyl 2-methylthiazole-4-carboxylate 
• 329203-85-2 2-methyl-4-[(trimethylsilyl)ethynyl]-1,3-thiazole 
• 107263-81-0 4-acetyl-2-methylthiazole semicarbazone 
• 23002-78-0 4-acetyl-2-methylthiazole 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS

This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract diso

Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol- 4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications

Recent genetic and pharmacological studies have suggested that the metabotropic glutamate receptor subtype 5 (mGluR5) may represent a druggable target in identifying new therapeutics for the treatment of various central nervous system disorders including drug abuse. In particular, considerable attention in the mGluR5 field has been devoted to identifying ligands that bind to the allosteric modulatory site, distinct from the site for the primary agonist glutamate. Both 2-methyl-6-(phenylethynyl)pyridine (MPEP) and its analogue 3-[(2-methyl-4-thiazolyl)ethynyl]pyridine (MTEP) have been shown to be selective and potent noncompetitive antagonists of mGluR5. Because of results presented in this study showing that MTEP prevents the reinstatement of cocaine self-administration caused by the presentation of environmental cues previously associated with cocaine availability, we have prepared a series of analogues of MTEP with the aim of gaining a better understanding of the structural features relevant to its antagonist potency and with the ultimate aim of investigating the effects of such compounds in blunting the self-administration of cocaine. These efforts have led to the identification of compounds showing higher potency as mGluR5 antagonists than either MPEP or MTEP. Two compounds 19 and 59 exhibited functional activity as mGluR5 antagonists that are 490 and 230 times, respectively, better than that of MTEP.

Design, synthesis and biological evaluation of novel, simplified analogues of laulimalide: Modification of the side chain

Novel, simplified analogues of the microtubule-stabilizing anticancer agent laulimalide, including the first derivatives with unnatural side chains, were designed by molecular modelling, synthesized by a late-stage diversification strategy, and evaluated in vitro for growth inhibition of human ovarian carcinoma cell lines (A2780, A2780/AD10).

Selenium Heterocycles. XXXVII. Synthesis of 4-(Thiazol-4-yl)-1,2,3-selenadiazoles and 4-(Selenazol-4-yl)-1,2,3-selenadiazoles

Starting from readily available 2-substituted-4-formylthiazoles and selenazoles, a series of 4-(2-aryl-4-selenazolyl)-1,2,3-selenadiazoles I and 4-(2-substituted-4-thiazolyl)-1,2,3-selenadiazoles II were prepared.Pyrolysis of compound II afforded (2-substituted-4-thiazolyl) acetylenes VII.Addition of potassium hydroxide pellets to an alcoholic solution of II gave 2-substituted-1,4-diselenafulvenes VIII.Decomposition of compound II with base followed by the addition of carbon disulfide gave 5-substituted 2-thioxo-1,3-thiaselenoles XI.